Immix Biopharma(IMMX) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

IMMX Immix Biopharma

Watchlist

1.680
-0.020-1.18%

Close Mar 31 16:00 ET

1.680
0.0000.00%

Post 16:05 ET

46.57MMarket Cap-2.21P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Immix Biopharma | 10-K: FY2024 Annual Report
SECMar 25 12:50 ET · Announcements
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
TipRanksFeb 10 10:25 ET · Ratings
Express News | Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy Designation For NXC-201
BenzingaFeb 10 09:36 ET
Several Insiders Invested In Immix Biopharma Flagging Positive News
Yahoo FinanceFeb 5 08:17 ET
Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation
MT NewswiresJan 7 10:56 ET
Express News | Immix Biopharma Inc: On Track for Next Program Update in Q1 2025
ReutersJan 7 09:35 ET

Comments

Teddy123

Feb 10 22:38

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

$Immix Biopharma (IMMX.US)$
Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Jaguar8

Feb 10 22:35

NEWS

$Immix Biopharma (IMMX.US)$
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
Monday, 10th February at 9:35 am
• FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis
• RMAT designation potentially streamlines the path to market approval by allowing frequent interactions with F...

Trytosaveabit

Dec 30, 2024 01:42

Insider buy!

$Immix Biopharma (IMMX.US)$

Jaguar8

Dec 19, 2024 22:35

NEWS

$Immix Biopharma (IMMX.US)$
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
Thursday, 19th December at 9:35 am
• All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10-6); all patients ...